Advances in Development and Application of Influenza Vaccines

Chen, Jidang; Wang, Jiehuang; Zhang, Jipei; Ly, Hinh

doi:10.3389/fimmu.2021.711997

Cited by 54 publications

(51 citation statements)

References 218 publications

(267 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Variable efficacy in adults but better efficacy in children [174]. Reversion to virulence or recombination with field virus is a possibility [175].…”

Section: Yesmentioning

confidence: 99%

A Review on Equine Influenza from a Human Influenza Perspective

Whitlock

Murcia

Newton

2022

Viruses

View full text Add to dashboard Cite

Influenza A viruses (IAVs) have a main natural reservoir in wild birds. IAVs are highly contagious, continually evolve, and have a wide host range that includes various mammalian species including horses, pigs, and humans. Furthering our understanding of host-pathogen interactions and cross-species transmissions is therefore essential. This review focuses on what is known regarding equine influenza virus (EIV) virology, pathogenesis, immune responses, clinical aspects, epidemiology (including factors contributing to local, national, and international transmission), surveillance, and preventive measures such as vaccines. We compare EIV and human influenza viruses and discuss parallels that can be drawn between them. We highlight differences in evolutionary rates between EIV and human IAVs, their impact on antigenic drift, and vaccine strain updates. We also describe the approaches used for the control of equine influenza (EI), which originated from those used in the human field, including surveillance networks and virological analysis methods. Finally, as vaccination in both species remains the cornerstone of disease mitigation, vaccine technologies and vaccination strategies against influenza in horses and humans are compared and discussed.

show abstract

“…Variable efficacy in adults but better efficacy in children [174]. Reversion to virulence or recombination with field virus is a possibility [175].…”

Section: Yesmentioning

confidence: 99%

A Review on Equine Influenza from a Human Influenza Perspective

Whitlock

Murcia

Newton

2022

Viruses

View full text Add to dashboard Cite

show abstract

“…Recent developments of adenovirus vector-based platforms, such as human Ad5 and Ad35 and chimpanzee adenoviruses (ChAd3, ChAdOx1, ChAd63), as vaccine vectors to express immunogenic proteins of influenza and other important pathogens, including LASV, have progressed at a fast pace with some of these viral vectored vaccines entering different human clinical trials [for reviews, see 175 , 176 ,]. An Ad5 (E1 and E2b-deleted) vector-based vaccine expressing the LASV NP or GPC protein was found to protect guinea pigs against lethal LASV challenge in a prime-and-boost vaccination strategy [ 126 ].…”

Section: Lf Therapeuticsmentioning

confidence: 99%

Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments

Murphy

2021

Virulence

Self Cite

View full text Add to dashboard Cite

Lassa fever (LF) is a deadly viral hemorrhagic disease that is endemic to West Africa. The causative agent of LF is Lassa virus (LASV), which causes approximately 300,000 infections and 5,000 deaths annually. There are currently no approved therapeutics or FDA-approved vaccines against LASV. The high genetic variability between LASV strains and immune evasion mediated by the virus complicate the development of effective therapeutics and vaccines. Here, we aim to provide a comprehensive review of the basic biology of LASV and its mechanisms of disease pathogenesis and virulence in various animal models, as well as an update on prospective vaccines, therapeutics, and diagnostics for LF. Until effective vaccines and/or therapeutics are available for use to prevent or treat LF, a better level of understanding of the basic biology of LASV, its natural genetic variations and immune evasion mechanisms as potential pathogenicity factors, and of the rodent reservoir-vector populations and their geographical distributions, is necessary for the development of accurate diagnostics and effective therapeutics and vaccines against this deadly human viral pathogen.

show abstract

“…The evolution of influenza vaccine development has shown a trend from traditional egg-dependent virus-based vaccines to safer, productive, and affordable modern vaccine technologies, [52,53] such as recombinant protein/peptide-and nucleic acid-based vaccine strategies (Figure 1b).…”

Section: Employment Of Modern Vaccine Typesmentioning

confidence: 99%

Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats

Dong

Wang

2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Influenza is one of the most severe and contagious respiratory infectious diseases. Influenza virus infection causes annual epidemics and occasional pandemics, resulting in an enormous health and economic burden worldwide. During the 2019-2020 flu season, the centers for disease control and prevention (CDC) estimates that flu caused 38 million illnesses, including 18 million medical visits, 405 000 hospitalizations, and 22 000 deaths in the United States. [1] Influenza viruses are enveloped RNA viruses of the Orthomyxoviridae family. Because the RNA polymerases lack the proofreading function, influenza viruses undergo constant antigenic drift and shift within animal and human reservoirs. [2] Influenza A viruses (IAVs) and influenza B viruses (IBVs) are the main circulating viruses that affect human health. So far, 18 hemagglutinin (HA) subtypes belonging to two HA phylogenetic groups and 11 neuraminidase (NA) subtypes have been identified for IAVs. [3] The IAVs H1N1 and H3N2 currently cause most epidemic diseases in humans. IBVs form a single antigenic group with two distinct lineages: Victoria and Yamagata.Seasonal vaccination is the most cost-effective method to combat influenza infection. However, current seasonal flu vaccines induce strain-specific immunity that rapidly wanes and displays low efficiencies against mismatched circulating strains and no effect on pandemics. The vaccines need annual reformulation based on the prediction by the WHO Global Influenza Surveillance and Response System to counter antigenic variations. [4] This uncertainty makes mismatches occur, resulting in suboptimal immunity. Fewer influenza cases occurred in the past 2020-2021 flu season in the United States than in any on record, [5] probably due to the widespread use of face masks and social distance to control COVID-19. The lack of exposure to the flu may make the population more susceptible to the virus when it returns. [6] Parallelly, predicting which strains will be circulating in the upcoming flu season and selecting vaccine manufacturing will be more challenging than ever.A next-generation universal influenza vaccine that elicits long-lasting cross-protective immunity against variant influenza strains will overcome the limitations of the current flu v accines. [7,8] Nanotechnology plays an indispensable role in the development of such vaccines. [9][10][11] Influenza viruses are nanosized particles enveloped by lipid membranes inserted with surface glycoprotein spikes. Nanoparticle vaccines can optimally mimic the influenza virus nanostructure with high antigen loads, facilitate targeted delivery and controlled antigen release, and synergize with molecular adjuvants to improve vaccine potency and breadth. Moreover, nanoparticle vaccines can facilitate rapid and scalable production, minimize cold-chain dependence, incorporate antigens in a flexibly modular fashion, and be affordably produced. Up to date, a variety of nanoparticle formulations have shown promising results in generating cross-reactive influenza immunity.

show abstract

Advances in Development and Application of Influenza Vaccines

Cited by 54 publications

References 218 publications

A Review on Equine Influenza from a Human Influenza Perspective

A Review on Equine Influenza from a Human Influenza Perspective

Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments

Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats

Contact Info

Product

Resources

About